Save
Glandular carcinomas of the cervix
ESGO eAcademy, Ate van der Zee, 232410
Cancer in pregnancy
ESGO eAcademy, Frederic Amant, 232409
Small cell and neuroendocrine tumours
ESGO eAcademy, Nicholas Reed, 232408
Carcinosarcoma, mucinous tumours, clear cell cancers & high grade serous cancers
ESGO eAcademy, Mansoor Raza Mirza, 232407
Keynote - Pathology of low grade tumours
ESGO eAcademy, Glenn McCluggage, 232394
Keynote - Molecular genetics of rare gynaecological cancers
ESGO eAcademy, David Huntsman, 232390
Quality of life and late treatments effects
ESGO eAcademy, Florence Joly, 232389
National and international registries & epidemiology
ESGO eAcademy, Domenica Lorusso, 232388
Approaches to treatment - organisation and central review
ESGO eAcademy, Mojgan Devouassoux, 232387
ESGO-ESMO Consensus conference on ovarian cancer standard treatment: final recommendations
ESGO eAcademy, Nicoletta Colombo, 232386
Management of non-epithelial ovarian malignancies
ESGO eAcademy, Cristiana Sessa, 219071
Adjuvant treatment in early, advanced and recurrent ovarian cancer
ESGO eAcademy, Mansoor Mirza, 219382
Video: surgical procedures in advanced ovarian cancer
ESGO eAcademy, Christina Fotopoulou, 219070
Surgical management of primary and recurrent ovarian cancer
ESGO eAcademy, Denis Querleu, 219381
Epidemiology and histopathology of ovarian cancer
ESGO eAcademy, Piotr Bernaczyk, 219069
Diagnosis and staging of ovarian cancer
ESGO eAcademy, Anna Fagotti, 219068
Management of surgical complications
ESGO eAcademy, Christina Fotopoulou, 219066
Symptom control and pain management (palliative care)
ESGO eAcademy, Cristiana Sessa, 219065
Perioperative care
ESGO eAcademy, Christina Fotopoulou, 219064
Familial gynecological cancer: risk assessment and management
ESGO eAcademy, Fedro Alessandro Peccatori, 219383
Diagnosis and management of uterine sarcoma
ESGO eAcademy, Michael Halaska, 219063
Fertility preserving options in endometrial cancer
ESGO eAcademy, Pawel Knapp, 219062
Video: laparoscopic paraaortic lymphadenectomy
ESGO eAcademy, Denis Querleu, 219061
Video: open paraaortic lymphadenectomy
ESGO eAcademy, Christina Fotopoulou, 219060
Adjuvant treatment of endometrial cancer
ESGO eAcademy, Mansoor Mirza, 219058
Surgical management of endometrial cancer
ESGO eAcademy, Denis Querleu, 219057
Diagnosis in endometrial cancer
ESGO eAcademy, Pawel Knapp, 219056
Epidemiology and histopathology of hyperplasia and endometrial cancer
ESGO eAcademy, Jaroslaw Swatek, 219055
Video: Partial/radical vulvectomy and groin node dissection, SLNM
ESGO eAcademy, Michael Halaska, 219054
Management of advanced stage and recurrent vulvar cancer
ESGO eAcademy, Mansoor Mirza, 219053
Primary treatment of early stage vulvar cancer
ESGO eAcademy, Kamil Zalewski, 219052
Epidemiology and histopathology
ESGO eAcademy, Piotr Bernaczyk, 219051
Fertility sparing procedures in cervical carcinoma (trachelectomy, NAC)
ESGO eAcademy, Michael Halaska, 219050
Video of radical hysterectomy (including nerve sparing)
ESGO eAcademy, David Cibula, 219049
Management of locally advanced carcinoma
ESGO eAcademy, Robert Jach, 219380
Cervical cancer: management of early invasive carcinoma
ESGO eAcademy, David Cibula, 219379
Ultrasound, MRI, staging in cervical cancer
ESGO eAcademy, Michael Halaska, 219046
Epidemiology and prevention of cervical cancer
ESGO eAcademy, Robert Jach, 219045
Surgical spaces, lymphatic drainage, nerves, topography
ESGO eAcademy, Denis Querleu, 219044
Ureteral reconstruction and Urinary conduits
ESGO eAcademy, Luis M. Chiva, 209153
Bowel surgery 
ESGO eAcademy, David Cibula, 209152
Bowel preparation
ESGO eAcademy, Dimitrios Haidopoulos, 209151
Video Assisted Thoracoscopic Surgery (VATS)
ESGO eAcademy, Murat Gultekin, 209150
Stomach mobilization - resection - placement of J-tube
ESGO eAcademy, Jalid Sehouli, 209149
Dissection of Porta Hepatis, Celiac Trunk and Techniques for Cholecystectomy
ESGO eAcademy, Denis Querleu, 209148
Splenectomy and Distal Pancreatectomy
ESGO eAcademy, David Cibula, 209147
Diaphragm stripping - resection - repair
ESGO eAcademy, Anna Fagotti, 209146
Liver Mobilization & Cardio-Phrenic LND
ESGO eAcademy, Luis M. Chiva, 209145
Morbidity and postoperatieve outcome
ESGO eAcademy, Jalid Sehouli, 209144
Nutrition
ESGO eAcademy, Philippe Morice, 209143
Preoperative and Postoperative evaluation of the advanced ovarian cancer patient
ESGO eAcademy, Stephanie Suria, 209142
Modified posterior exenteration and Excision of the pouch of Douglas sparing the rectum
ESGO eAcademy, Philippe Morice, 209141
Pelvic and Paarotic llymphadenectomy
ESGO eAcademy, Denis Querleu, 209140
Evaluation of the extension of the disease
ESGO eAcademy, Anna Fagotti, 209139
Science of tissue management - energy and hemostats, stapplers, ednocutters
ESGO eAcademy, Dimitrios Haidopoulos, 209138
Surgery in advanced epithelial ovarian cancer - Quality control
ESGO eAcademy, Luis M. Chiva, 211211
The aim of cytoreduction in ovarian cancer surgery
ESGO eAcademy, Murat Gultekin, 209137
CURRENT AND FUTURE DIRECTIONS FOR GRANULOSA CELL TUMOUR MANAGEMENT
ESGO eAcademy, Isabelle Ray-Coquard, 202840
WHAT IS THE STATE-OF-THE-ART FOR OVARIAN GERM CELL TUMOURS?
ESGO eAcademy, Jalid Sehouli, 202839
HEREDITARY GYNAECOLOGICAL CANCERS: PREVENTION AND ROLE OF PROPHYLACTIC SURGERIES
ESGO eAcademy, Ranjit Manchanda, 202843
HOW CAN WE ELIMINATE DEATHS IN HIGH RISK GTN?
ESGO eAcademy, Michael Seckl, 202838
STATE OF ART IN SCREENING OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Murat Gultekin, 202842
RECENT DEVELOPMENTS IN GTD AND MOLAR PREGNANCIES
ESGO eAcademy, Leon Massuger, 202837
THE IMPACT OF HEALTHY LIFE STYLE AND OBESITY ON PREVENTION OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Maria Kyrgiou, 202841
LAPAROSCOPIC VERSUS OPEN TREATMENT OF ENDOMETRIAL CANCER IN ELDERLY WOMEN
ESGO eAcademy, Ignacio Zapardiel, 202833
PREDICTIVE MARKERS IN CERVICAL CANCER
ESGO eAcademy, Cornelis D de Kroon, 203136
ELDERLY PATIENTS UNDERGOING SURGERY FOR OVARIAN OR CERVICAL CANCER: PERI-OPERATIVE ASSESSMENT AND SURGICAL CHOICES
ESGO eAcademy, Dina Kurdiani, 202832
PREDICTIVE MARKERS IN OVARIAN CARCINOMA
ESGO eAcademy, Alexandra Leary, 202835
FRAILTY EVALUATION AND MEDICAL TREATMENT OF ELDERLY POPULATION WITH GYNAECOLOGICAL MALIGNANCIES
ESGO eAcademy, Annamaria Ferrero, 202831
PREDICTIVE MARKERS IN ENDOMETRIAL CARCINOMA
ESGO eAcademy, Xavier Matias-Guiu, 202834
SUPPORTIVE CARE FOR WOMEN WITH GYNAECOLOGIC CANCER RECEIVING EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY
ESGO eAcademy, Alina Sturdza, 202830
SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS RECEIVING MEDICAL TREATMENT
ESGO eAcademy, Jørn Herrstedt, 202829
PERIOPERATIVE SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS
ESGO eAcademy, Felix Hilpert, 202828
CERVICAL ADENOCARCINOMA IB1 AFTER RADICAL HYSTERECTOMY, POSITIVE LYMPHNODES - EVALUATION OF PERIAORTIC NODES, ADJUVANT THERAPY, MANAGEMENT OF OVARIES
ESGO eAcademy, Sebastien Gouy, 202824
CASE 3: DISTANT METASTASES, ENDOCRINE THERAPY, CHEMOTHERAPY
ESGO eAcademy, Guenter Emons, 202827
PLATINUM ELIGIBLE RECURRENT OVARIAN CANCER
ESGO eAcademy, Cristiana Sessa, 202820
CERVICAL CANCER IB1, 2CM TUMOR DIAMETER: SLN BIOPSY, MANAGEMENT IN REGARD TO ABSENCE/PRESENCE OF METASTATIC DISEASE
ESGO eAcademy, Alexander W. Reinthaller, 202823
CASE 2: ADVANCED, METASTATIC, TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY
ESGO eAcademy, Melanie Powell, 202826
RECURRENT OVARIAN CANCER - ROLE OF SURGERY
ESGO eAcademy, Philipp Harter, 202819
SURGICAL MANAGEMENT IN PRIMARY OVARIAN CANCER
ESGO eAcademy, Giovanni Aletti, 202818
CERVICAL CANCER STAGE IB1, 3CM TUMOR DIAMETER: EVALUATION OF LYMPH NODES, RISK FACTORS AND THERAPEUTIC MANAGEMENT
ESGO eAcademy, Remi Nout, 202822
CASE 1: ADVANCED ENDOMETRIAL CANCER, AMENABLE TO SURGICAL RESECTION, ROLE OF NEOADJUVANT CHEMOTHERAPY
ESGO eAcademy, Frederic Amant, 202825
CURRENT CLINICALLY MEANINGFUL ASPECTS IN HEREDITARY UTERINE CANCER INCLUDING LYNCH SYNDROME
ESGO eAcademy, Uzi Beller, 202814
THE IMMUNOTHERAPY STORY
ESGO eAcademy, Lana Kandalaft, 202817
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY OVARIAN CANCER
ESGO eAcademy, Pauline Wimberger, 202813
THE PARP-I STORY
ESGO eAcademy, Andres Poveda, 202816
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY BREAST CANCER
ESGO eAcademy, Jan Lubinski, 202812
SURGICAL TRAILS
ESGO eAcademy, Andreas Du Bois, 202815
Conservative surgery for the treatment of granulosa cell tumors of the ovary: results from the MITO 9 study
ESGO eAcademy, Alice Bergamini, 202926
A COMPARATIVE STUDY OF TWO FOLLOW-UP STRATEGIES FOLLOWING TREATMENT OF ENDOMETRIAL CANCER BETWEEN AN ITALIAN AND A UK CENTRE
ESGO eAcademy, Valentina Ghirardi, 203531
HOW TO ASSESS RESECTABILITY AT PRIMARY SURGERY?
ESGO eAcademy, Anna Fagotti, 202808
WHICH ROLE CAN PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE HAVE IN CLINICAL TRIALS
ESGO eAcademy, Remi Nout, 202811
Prospective Clinical Cohort Study For Efficacy Assessment Of Topical Treatment With Olivoleina On Post-Surgical Scars In Patients Undergoing Radiotherapy For Gyneacologic Cancers
ESGO eAcademy, Jesus Molero Vilchez, 202925
ANGIOGENESIS
ESGO eAcademy, sandro pignata, 202807
HOW TO INTEGRATE PATIENT REPORTED OUTCOME TOOLS IN THE EVERYDAY GYNAECOLOGICAL CANCER CLINIC
ESGO eAcademy, Galina Velikova, 202810
BRCA/HRD
ESGO eAcademy, Jonathan Ledermann, 202806
OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER
ESGO eAcademy, Lonneke van de Poll-Franse, 202809
MANAGEMENT OF RECURRENT DISEASE
ESGO eAcademy, Frederic Amant, 202799
CERVICAL CANCER IMMUNOTHERAPY TRIAL
ESGO eAcademy, Hans Nijman, 202804
CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Dimitrios Haidopoulos, 202798
OVARIAN CANCER IMMUNOTHERAPY TRIALS
ESGO eAcademy, Jonathan Ledermann, 202803
RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Nicoletta Colombo, 202797
RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Vesna Kesic, 202796
PRINCIPLES OF IMMUNOTHERAPY
ESGO eAcademy, Christian Marth, 202801
Prognostic Value Of Lymph Node Ratio And Number Of Positive Inguinal Nodes In Patients With Vulvar Cancer
ESGO eAcademy, Richard Schwameis, 202924
ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS
ESGO eAcademy, Frederic Amant, 202790
MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS
ESGO eAcademy, Clare Scott, 202793
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
ESGO eAcademy, Sarah Blagden, 202788
CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
ESGO eAcademy, Charlie Gourley, 202787
CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES
ESGO eAcademy, Cristiana Sessa, 202792
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
ESGO eAcademy, Willemien J. Van Driel, 202786
ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
ESGO eAcademy, Jonathan Ledermann, 202785
UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS
ESGO eAcademy, Iain McNeish, 202791
CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE
ESGO eAcademy, Mansoor Mirza, 202781
Vulvar Cancer In Ireland: Analysis Of The Irish National Cancer Registry Over A 20 Year Period
ESGO eAcademy, Ann Rowan, 203117
STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY
ESGO eAcademy, sandro pignata, 202780
PLATINUM-RESISTANT DISEASE: CURRENT STATUS
ESGO eAcademy, Nicole Concin, 202779
RANKL -BONES, SEX, AND BREAST CANCER
ESGO eAcademy, Josef Penninger, 202794
WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
ESGO eAcademy, Christian Marth, 202795
GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)
ESGO eAcademy, Christine Haie-Meder, 202775
WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202778
IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY
ESGO eAcademy, Akila Viswanathan, 202774
WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER
ESGO eAcademy, Alain G. Zeimet, 202777
CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS
ESGO eAcademy, Jacob Lindegaard, 202773
WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER
ESGO eAcademy, David Church, 202776
Interval Between  Cytoreductive Surgery And Adjuvant Chemotherapy Is Associated With Overall Survival In  Patients With Advanced Ovarian Cancer
ESGO eAcademy, Maite Timmermans, 202923
Outcomes Of Robotic Radical Hysterectomy For Cervical Cancer In Comparison To Laparotomy ; A Population Based Study In The United States
ESGO eAcademy, Sabrina Piedimonte, 202922
TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY
ESGO eAcademy, Alexandra Taylor, 202769
IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS
ESGO eAcademy, Kathrin Kirchheiner, 202772
ADJUVANT TREATMENT
ESGO eAcademy, Carien Creutzberg, 202768
PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH
ESGO eAcademy, Michal Zikan, 202771
DIAGNOSTIC AND SURGICAL MANAGEMENT
ESGO eAcademy, Philippe Morice, 202767
SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT
ESGO eAcademy, Moniek M ter Kuile, 202770
Cervical Cancer Relapse Rates In Patients With Para-Aortic Negitive PET Scans:A Five-Year Analysis In An Irish Gynaeoncology Centre
ESGO eAcademy, Ann Rowan, 202921
Discussion and Closing
ESGO eAcademy, sandro pignata, 202898
Patterns Of Lymph Node Metastases In Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.
ESGO eAcademy, Lucas Minig, 202920
Future therapies
ESGO eAcademy, Kathleen Moore, 202897
Adjuvant management
ESGO eAcademy, Nicoletta Colombo, 202896
Long-Term Efficacy And Immunogenicity Of The 9-Valent Human Papillomavirus Vaccine: Final Analyses Of A Double-Blind, Randomized Clinical Study
ESGO eAcademy, Elmar A. Joura, 202919
Primary debulking strategy
ESGO eAcademy, Sven Mahner, 202895
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, sandro pignata, 202766
Mucinous Ovarian Cancer (MOC): What Is The Reproducibility Of The WHO Classification?
ESGO eAcademy, Mojgan Devouassoux, 202918
Refinement Of High-Risk Endometrial-Cancer (HR-EC) Classification Using DNA Damage Response (DDR) Biomarkers: A Transportec Initiative
ESGO eAcademy, Aurélie AUGUSTE, 202917
PERIOPERATIVE CARE OF THE ELDERLY PATIENT
ESGO eAcademy, Karl Tamussino, 202765
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE
ESGO eAcademy, Richard Poetter, 202761
Adverse Events After Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Stage III Ovarian Cancer: Phase III OVHIPEC Study
ESGO eAcademy, Simone Koole, 202916
MANAGEMENT OF EARLY STAGES
ESGO eAcademy, David Cibula, 202760
Perioperative Positioning Management In Gynecologic Cancer Surgery: A National NOGGO-AGO Intergroup Survey
ESGO eAcademy, Jenny Katharina Wagner, 202915
WHAT´S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW
ESGO eAcademy, Stephanie Suria, 202763
PATHOLOGY REPORT   
ESGO eAcademy, Maria Rosaria Raspollini, 202759
SHAPING NEW CLINICAL PRACTICE GUIDELINES
ESGO eAcademy, David Cibula, 202758
INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES
ESGO eAcademy, Lena Wijk, 202762
Hormonal And Fertility Outcome After Fertility Sparing Surgery And Chemotherapy For Ovarian Neoplasms: A Retrospective Study
ESGO eAcademy, Lorenzo Ceppi, 202914
MRI-Based Predictive Factors Of Axillary Lymph Node Metastases In Breast Cancer
ESGO eAcademy, David Atallah, 202913
Experience In Introducing Sentinel Lymph Node Biopsy In Early- Stage Vulva Cancer: A Single Institution Based Prospective Study
ESGO eAcademy, Ligita Paskeviciute Frøding, 202912
ESGO – A STORY OF SUCCESS
ESGO eAcademy, David Cibula, 202757
INTRODUCTION
ESGO eAcademy, Luis M. Chiva, 202756
SUMMARY AND CONCLUSIONS
ESGO eAcademy, Gabriele Calaminus, 202755
TREATMENT OF RECURRENT AND METASTATIC DISEASE
ESGO eAcademy, Ate van der Zee, 202749
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Cristiana Sessa, 202754
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Dominik Schneider, 202753
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Philippe Morice, 202752
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Gabriele Calaminus, 202751
DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP
ESGO eAcademy, Maaike Oonk, 202747
Practical experiences from CTCA at Southeastern RegionalMedical Center, Georgia USA
ESGO eAcademy, Mansoor Raza Mirza, 202740
Pathological aspects of uterine carcinocarcoma
ESGO eAcademy, Mojgan Devouassoux, 202903
Practical experiences from Klinik für Gynäkologie, Die Charité – Universitätsmedizin Berlin, Germany
ESGO eAcademy, Jacek Grabowski, 202739
CONCLUSION
ESGO eAcademy, Andreas Du Bois, 202736
Q&A and Discussion
ESGO eAcademy, Session Speakers, 203120
SELECTING PATIENTS FOR PARP INHIBITION
ESGO eAcademy, Mansoor Mirza, 202735
RELAPSED OVARIAN CANCER: WHAT DOES MAINTENANCE THERAPY OFFER?
ESGO eAcademy, Nicoletta Colombo, 202733
Welcome and introduction
ESGO eAcademy, Christian Marth, 202732
QUESTIONS REMAINED TO BE ANSWERED
ESGO eAcademy, David Cibula, 202728
CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Catherine Alix-Panabieres, 202731
SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS
ESGO eAcademy, Nadeem Abu Rustum, 202727
DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Heidi Fiegl, 202730
WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Adriaan Vanderstichele, 202729
Ultrasound Characteristics Of Endometrial Cancer As Defined By The International Endometrial Tumor Analysis (IETA) Consensus Nomenclature- A Prospective Multicenter Study
ESGO eAcademy, Daniela Fischerova, 202910
LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.
ESGO eAcademy, Domenica Lorusso, 202722
UTERINE CORPUS
ESGO eAcademy, Sigurd Lax, 202725
WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?
ESGO eAcademy, Isabel Carriles, 202721
OVARY AND FALLOPIAN TUBE
ESGO eAcademy, Xavier Matias-Guiu, 202724
PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL
ESGO eAcademy, Sarah Kitson, 202719
CERVIX, VULVA, VAGINA
ESGO eAcademy, Glenn McCluggage, 202723
Development And Pre-Testing Of The Eortc Quality Of Life Questionnaire For Vulva Cancer Patients – The Significance Of Patient Involvement
ESGO eAcademy, Pernille Jensen, 202909
Closing and remarks
ESGO eAcademy, Andreas Du Bois, 202716
Being Practical Case 3
ESGO eAcademy, Christian Marth, 202715
Being Practical Case 2
ESGO eAcademy, Nicoletta Colombo, 202714
Being Practical Case 1
ESGO eAcademy, Isabelle Ray-Coquard, 202713
SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
ESGO eAcademy, Felix Hilpert, 202712
Introduction
ESGO eAcademy, Andreas Du Bois, 202711
Prognostic Factors For Local Recurrence Of Squamous Cell Carcinoma Of The Vulva: A Systematic Review
ESGO eAcademy, Nienke Te Grootenhuis, 202908
The New Normal; Sexual Function after Ovarian Cancer for Survivors and Partners Compared to Normdata
ESGO eAcademy, Maria Caroline Vos, 202907
HOW LONG SHOULD HORMONAL TREATMENT BE CONTINUED BEFORE DECIDING FOR HYSTERECTOMY IN THE FERTILITY SPARING MANAGEMENT OF ENDOMETRIAL CANCER?
ESGO eAcademy, Nicoletta Colombo, 202704
VULVA CANCER
ESGO eAcademy, Ate van der Zee, 202709
The Role Of The Peritoneal Cancer Index In Surgery For Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202906
FERTILITY SPARING MANAGEMENT IN CERVICAL CANCERS BETWEEN 2 AND 4 CM: RADICAL TRACHELECTOMY BY LAPAROTOMY OR NEO-ADJUVANT CHEMOTHERAPY?
ESGO eAcademy, Ignance Vergote, 202703
OVARIAN CANCER
ESGO eAcademy, Christoph Grimm, 202708
The Peritoneal Cancer Index(PCI): Selted Regions - And Not The Total PCI - Are Predictive Of Survival In Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202905
CAN WE SAFELY USE OVARIAN HYPERSTIMULATION IN INFERTILE PATIENTS AFTER FSS FOR EPITHELIAL TUMORS?
ESGO eAcademy, Dominik Denschlag, 202702
CERVICAL CANCER
ESGO eAcademy, Daniela Fischerova, 202707
FERTILITY SPARING MANAGEMENT IN HIGH RISK EPITHELIAL OVARIAN CANCER
ESGO eAcademy, Enrica Bentivegna, 202701
Imaging in the diagnosis and management of endometrial cancer
ESGO eAcademy, Ingfrid Haldorsen, 202706
CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.
ESGO eAcademy, Ilary Ruscito, 202699
CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)
ESGO eAcademy, Umesh Mahantshetty, 202698
AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS
ESGO eAcademy, Isabelle Ray-Coquard, 202697
EMBRACE THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202696
Randomized Controlled Phase III Study To Evaluate Secondary Cytoreductive Surgery In Platinum-Sensitive Recurrent Ovarian Cancer - AGO Desktop III/ENGOT Ov20
ESGO eAcademy, Jalid Sehouli, 202904
Medical treatment of uterine carcinosarcoma
ESGO eAcademy, Isabelle Ray-Coquard, 190586
Surgical treatment of serous endometrial cancer
ESGO eAcademy, Frederic Guyon, 190585
Surgical treatment of low grade serous ovarian cancer
ESGO eAcademy, Jalid Sehouli, 180471
Medical Tumor Therapy for Germ Cell Tumors of Adults
ESGO eAcademy, Michael Seckl, 180466
Systemic treatment for low grade serous carcinoma
ESGO eAcademy, Michael Seckl, 180469
Surgical treatment for malignant germ cell tumor.
ESGO eAcademy, Pauline Wimberger, 180467
Pathologic aspects of Germ Cell Tumors
ESGO eAcademy, Doris Mayr, 180468
Pathologic aspects of Low Grade Serous Ovarian Cancer
ESGO eAcademy, Doris Mayr, 180470
Look into the future: Medical treatment of ovarian cancer in 2026
ESGO eAcademy, Ignance Vergote, 173572
Immunotherapy in gynecological malignancies
ESGO eAcademy, An Coosemans, 173570
Why do studies of targeted treatment fail?
ESGO eAcademy, Jonathan Ledermann, 173568
Targeting PARP: Mechanisms of action, available evidence, selection of patients, management of toxicities
ESGO eAcademy, Jonathan Ledermann, 173567
Targeting tyrosine kinases
ESGO eAcademy, Jonathan Ledermann, 173566
Molecular pathways in cervical cancer
ESGO eAcademy, Heidi Lyng, 173565
Molecular pathways in endometrial cancer
ESGO eAcademy, Henrica Maria Johanna Werner, 173564
Molecular pathways of low-grade ovarian cancer
ESGO eAcademy, Kristina Lindemann, 173563
Molecular pathways of high grade ovarian cancer
ESGO eAcademy, Adriaan Vanderstichele, 173562
Surgical aspects of uterine carcinosarcoma (~ serous)
ESGO eAcademy, Frederic Amant, 173558
Uterine carcinosarcoma: radiotherapy
ESGO eAcademy, Carien Creutzberg, 173556
Serous endometrial cancer: radiotherapy
ESGO eAcademy, Carien Creutzberg, 173557
Serous endometrial cancer: current management and targeted therapies
ESGO eAcademy, Annamaria Ferrero, 173555
Adjuvant Treatment and Place of Radiation Therapy in Vulvar Cancer
ESGO eAcademy, Carien Creutzberg, 150846
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
ESGO eAcademy, Mansoor Raza Mirza, 154789
New ESGO Guidelines of Management of Vulvar Cancer
ESGO eAcademy, Ate van der Zee, 150845
How to Stage Locally Advanced Cervical Cancer (Radiological and Surgical) before Chemoradiation Therapy
ESGO eAcademy, Sebastien Gouy, 150844
Management of the Clear Cell Ovarian Carcinoma
ESGO eAcademy, Keiichi Fujiwara, 150843
Phase 2: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Jonathan Ledermann, 150268
Surrogate Endpoints
ESGO eAcademy, Paolo Bruzzi, 150266
Phase 1/1B: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Cristiana Sessa, 150267
Statistical Plans, Interim Analysis and Subgroup Analysis
ESGO eAcademy, Paolo Bruzzi, 150265
Vulvar Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Fabio Landoni, 150264
Endometrial Cancer: What Do We Know? What Don't We Know ? What Should Be Investigated?
ESGO eAcademy, Eric Pujade-Lauraine, 150263
Uterine Sarcoma: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Andres Poveda, 150262
Cervical Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Christian Marth, 150261
Welcome & Introduction
ESGO eAcademy, Nicoletta Colombo, 150269
New Classification of Uterine Sarcoma
ESGO eAcademy, Sabrina Croce, 147380
Gastric-type Mucinous Cervical Adenocarcinoma
ESGO eAcademy, Mojgan Devouassoux, 148332
Vulvovaginal Glandular Neoplasia
ESGO eAcademy, Mojgan Devouassoux, 148333
Pathology of Clear Cell Ovarian Tumors
ESGO eAcademy, Ester Oliva, 147379
New Classification and Molecular of Endometrial Cancers
ESGO eAcademy, Sigurd Lax, 147381
Pathologic Characteristics of Mucinous Tumors (Borderline and Invasive: Infltrative/expansile Subtypes)
ESGO eAcademy, Sigurd Lax, 147383
Pathological and Molecular Classification of Epithelial Ovarian Cancer
ESGO eAcademy, Sigurd Lax, 147382
Restoring the Function of Mutated P53 - a Major Contribution to Carcinogenesis
ESGO eAcademy, John A Green, 147116
Genetic Testing in Ovarian Cancer Patients: How Far Should We Go
ESGO eAcademy, Charlie Gourley, 147115
Adjuvant Therapeutic Approaches by Histological Subtype with Implications for Treatment
ESGO eAcademy, Jonathan Ledermann, 147114
Prophylactic Surgery in High Risk Population
ESGO eAcademy, Christina Fotopoulou, 147112
Laser Skinning Vulvectomy
ESGO eAcademy, Michael G. Halaska, 147110
LEEP/LLETZ and Needle Conization
ESGO eAcademy, Ilker Selcuk, 147109
Cold Knife Conization and Sturmdorf Technique
ESGO eAcademy, Ignacio Zapardiel, 147108
Simple Solutions for Developing Countries for Breast Cancer Screening
ESGO eAcademy, Murat Gultekin, 147106
Current Situation of Breast Cancer Screening Startegies in Europe and Around the World
ESGO eAcademy, Larry von Karsa, 147105
Evaluation of Mammography for the Detection of Breast Cancer in Screening Programs
ESGO eAcademy, Peter Dean, 147104
Molecular Cancer Genetics
ESGO eAcademy, Henrica Maria Johanna Werner, 147103
Endometrial Cancers Prevention and Screening Methods
ESGO eAcademy, Thierry A.M. Van Den Bosch, 147102
Chemoprevention of Endometrial Cancers
ESGO eAcademy, Pauline Wimberger, 147100
Obesity and Gynaecological Cancers
ESGO eAcademy, Maria Kyrgiou, 147099
Follow-up and Treatment of Recurrences
ESGO eAcademy, Vesna Kesic, 147098
Should CIN2 Lesions Be Treated and When?
ESGO eAcademy, Maria Kyrgiou, 147097
Screening after Vaccination
ESGO eAcademy, Jack Cuzick, 147096
Novel Molecular Techniques in Screening & Diagnosis & Prediction
ESGO eAcademy, Jack Cuzick, 147094
Cytology vs. HPV for Primary Screening
ESGO eAcademy, Marc Arbyn, 147093
Cervical Cancer Screening in Low and High Resource Settings
ESGO eAcademy, Partha Basu, 147092
HPV Prophylactic Vaccines: Lessons Learned from 10 Years Experiences
ESGO eAcademy, Xavier Bosch, 147090
HPV Related Cancers: the Comparative Figures in the World
ESGO eAcademy, Partha Basu, 147089
The Human Papillomavirus Types and the Type-specific Risks for Disease
ESGO eAcademy, Joakim Dillner, 147088
Quality Assurance for the Surgical Management of Ovarian Cancer and ESGO Certification
ESGO eAcademy, Denis Querleu, 139309
Goals and Limits of Surgery in Advanced Ovarian Cancer
ESGO eAcademy, Luis M. Chiva, 139308
Combining a Surgical and Treatment Question in the Same Trial. Is It Feasible?
ESGO eAcademy, Mansoor Raza Mirza, 135850
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: a Unique Opportunity for Traslational Research
ESGO eAcademy, sandro pignata, 135849
Algorithm To Select Patients for Primary Cytoreductive Surgery versus Neoadjuvant Chemotherapy
ESGO eAcademy, Christian Marth, 135848
Quality Assessment in Ovarian Cancer Surgery
ESGO eAcademy, Andreas Du Bois, 135847
Immune Check Points
ESGO eAcademy, Iain McNeish, 135846
Cell Cycle Check Points
ESGO eAcademy, Cristiana Sessa, 135845
P53
ESGO eAcademy, Nicole Concin, 135844
Defective DNA Repair as a Target in Ovarian Cancer
ESGO eAcademy, Ignance Vergote, 135843
Results from Group C: Lights and Shadows on Rare Ovarian Tumors
ESGO eAcademy, Nicoletta Colombo, 135842
Results from Group D: Lights and Shadows on Stratification Factors, Control Groups and Endpoints in Recurrent Disease
ESGO eAcademy, Eric Pujade-Lauraine, 135841
Results from Group B: Lights and Shadows on Control Groups and Endpoints in Front Line
ESGO eAcademy, Nicoletta Colombo, 135840
How To Organize a Consensus Conference: Methodology and SOPs
ESGO eAcademy, Andreas Du Bois, 135838
Results from Group A: Lights and Shadows on Stratification Factors (Clinical, Pathologic and Molecular) in Front Line
ESGO eAcademy, Andrés Poveda, 135839
Intra-cavitary and Interstitial Image Guided Brachytherapy in Locally Advanced Cervical Cancer
ESGO eAcademy, Christine Haie-Meder, 131621
Particularity of the Surgical Management of Mucinous Ovarian Tumors
ESGO eAcademy, Philippe Morice, 131619
Molecular Characteristics, Trials and Targeted Therapies in Clear Cell Ovarian Tumors
ESGO eAcademy, Alexandra Leary, 131618
Molecular Characteristics, Trials and Targeted Therapies in Mucinous Ovarian Tumors
ESGO eAcademy, Alexandra Leary, 131617
Particularities of Anesthesiologic Management of Debulking Surgery in Ovarian Cancer
ESGO eAcademy, Stephanie Suria, 131616
ESGO – EBCOG - Teach the Visitors Modules - Training Course for Hospital Visitors
ESGO eAcademy, Prof. René H.M. Verheijen and Michael J. Halaska, 128206
ESGO - Fellow Training
ESGO eAcademy, Rene H.M. Verheijen, 128205
Treatment of NE Cancers of Genital Tract
ESGO eAcademy, Nicholas Reed, 117678
Pathology of Neuroendocrine Tumours of Genital Tract
ESGO eAcademy, Sigurd Lax, 117677
Treatment of Sex Cord and Stromal Tumours
ESGO eAcademy, Isabelle Ray-Coquard, 117676
Pathology of Sex Cord and Stromal Tumours
ESGO eAcademy, Mojgan Devouassoux, 117675
Panel Discussion to Video Series on Surgical Treatment of Early Stage Cervical Cancer
ESGO eAcademy, Speakers Session, 117660
Place of Interventional Radiology in the Management of Immediate and Late Postoperative Complications
ESGO eAcademy, Frederic Deschamps, 117672
Radio-Induced Chronic Enteritis in Uterine Cancer: How To Prevent, How To Manage?
ESGO eAcademy, Jervoise Andreyev, 117671
QOL after Radical Surgery in Cervical/Endometrial Cancer
ESGO eAcademy, Elena Ulrikh, 117670
New Nuclear Medicine Approaches-Beyond FDG
ESGO eAcademy, Jean-Noël Talbot, 117648
Image Guided Adaptive Brachytherapy for Vaginal Cancer, Vaginal Recurrences and Endometrial Cancer
ESGO eAcademy, Remi Nout, 117651
Imaging Lymph Nodes and Recurrent/Relapsed Disease
ESGO eAcademy, Andrea Rockall, 117647
Image Guided Adaptive Brachytherapy for Cervical Cancer Combined with External Beam Radiochemotherapy
ESGO eAcademy, Richard Pötter, 117650
Imaging the Primary Site (Cervix, Endometrium, Ovaries, Peritoneum)
ESGO eAcademy, Nandita de SOUZA, 117646
Advances in Pelvic External Beam Image Guided Adaptive Radiochemotherapy
ESGO eAcademy, Richard Pötter, 117937
Faults in Colposcopy
ESGO eAcademy, Vesna Kesic, 117645
Current Role of Colposcopy in Diagnostics of Low Genital Tract Pathology
ESGO eAcademy, Jiri Slama, 117644
The Future Role of Biological Markers in the Surgical Treatment Planning
ESGO eAcademy, MICHAEL BIRRER, 117640
Immunotheraoy of Ovarian Cancer
ESGO eAcademy, Eric Pujade-Lauraine, 117643
How To Select the Patients in an Appropriated and Dedicated Surgical Center?
ESGO eAcademy, Giovanni Aletti, 117639
Therapeutic Vaccines for Cervical Cancer
ESGO eAcademy, Cornelis Melief, 117642
Any Borders in Cytoreductive Surgery? Which Are?
ESGO eAcademy, Christina Fotopoulou, 117638
Ovarian Cancer: Ovarian Management in Young Patients with BRCA-Mutations
ESGO eAcademy, Catherine Uzan, 117637
Lymphadenectomy
ESGO eAcademy, Christhardt Koehler, 117633
Endometrial Cancer: Clinical Recommendation for Conservative Treatment in Low Risk Disease
ESGO eAcademy, Alexander Rodolakis, 117636
Radical Hysterectomy (Cons)
ESGO eAcademy, Christophe Pomel, 117632
Breast Cancer: Ovarian Damage by Systemic Treatment and the Role of Protection by GNRH Analogues
ESGO eAcademy, Dominik Denschlag, 117635
Lymphadenectomy
ESGO eAcademy, Henrik Falconer, 117631
Robot vs Laparoscopy: Chair
ESGO eAcademy, K. Rainer Kimmig, 117628
Radical Hysterectomy (Pros)
ESGO eAcademy, Angelo Maggioni, 117630
Personalised Risk Prediction and Prevention - the Role of Social Media Networks
ESGO eAcademy, Caroline Presho, 117623
Recurrent Ovarian Cancer and Hipec
ESGO eAcademy, Philipp Harter, 117627
Personalised Treatment in Women´s Cancer
ESGO eAcademy, Helga B Salvesen, 117622
Primary Ovarian Cancer
ESGO eAcademy, Sven Mahner, 117626
An Update on Current Strategies For Women´s Cancer Prevention
ESGO eAcademy, Jack Cuzick, 117621
Surgical Trials (EBM): Endometrial Cancer
ESGO eAcademy, Stefano Greggi, 117625
Cervical and Vulvar Cancer
ESGO eAcademy, Marie Plante, 117624
MIS, Next Step: Image Guided Surgery
ESGO eAcademy, Jacques Marescaux, 117619
Radiation Therapy and Anti-Hpv Treatment
ESGO eAcademy, Eric Deutsch, 117618
Stage IIB-III: How Can We Improve Outcomes for Advanced Cervical Cancer?
ESGO eAcademy, Gillian Thomas, 117613
Dose Adaptation for Pelvic / Para-Aortic Nodes
ESGO eAcademy, Ina Jϋrgenliemk-Schulz, 117617
Stage IB2: Radical Hysterectomy or Chemoradiation?
ESGO eAcademy, Denis Querleu, 117612
Is Radical Hysterectomy Necessary in Low Volume Disease?
ESGO eAcademy, Pedro Ramirez, 117611
Brachytherapy Data: Which Doses for Which Tumours?
ESGO eAcademy, Christine Haie-Meder, 117918
Systemic Treatment, Including Adjuvant
ESGO eAcademy, Patricia Pautier, 117610
Surgery
ESGO eAcademy, Frederic Amant, 117609
Pathology
ESGO eAcademy, Catherine Genestie, 117608
Systemic Treatment, Including Adjuvant
ESGO eAcademy, Patricia Pautier, 117607
Surgery
ESGO eAcademy, Frederic Amant, 117606
Pathology
ESGO eAcademy, Catherine Genestie, 117605
Complex Vaccination Strategies in Cervical Cancers
ESGO eAcademy, Suzy Scholl, 117600
Clinical Applications of Molecular and Genetic Predictive Factors in Endometrial Cancer
ESGO eAcademy, MICHAEL BIRRER, 117595
Controversies in the Management of Intermediate Risk Endometrial Cancer
ESGO eAcademy, Mansoor Raza Mirza, 117594
Overview on HPV Trials and an Update on Recent Advances on HPV Research
ESGO eAcademy, Gemma G. Kenter, 117598
Role of Radiation Therapy in Intermediate Risk Group
ESGO eAcademy, Carien Creutzberg, 117593
Immunotherapy Approaches in Ovarian Cancer
ESGO eAcademy, Petronella B. Ottevanger, 117597
Surgical Staging and Potential Role of Sentinel Node Biopsy
ESGO eAcademy, Sean C. Dowdy, 117592
Risk Communication in Oncogenetics
ESGO eAcademy, Jan Oosterwijk, 117590
Advanced and Recurrent Disease
ESGO eAcademy, Jonathan Ledermann, 117587
Adjuvant Treatment
ESGO eAcademy, Remi Nout, 117586
Implementation of BRCA Sequencing in an Oncology Clinic
ESGO eAcademy, Susana Banerjee, 117589
Surgery
ESGO eAcademy, Christian Marth, 117585
Prevention and Screening
ESGO eAcademy, Frederic Amant, 117584
Molecular Testing in Ovarian Cancer; How Far Should We Go?
ESGO eAcademy, Charlie Gourley, 117588
Evaluation of Self-Collected Vaginal Samples and Urine an a Test-of-Cure Setting
ESGO eAcademy, Sonia Andersson, 117578
Tissue and Imaging Biomarkers for Hypoxia Predicts Poor Outcome in Endometrial Cancer
ESGO eAcademy, Anna Berg, 117577
Surgical Management of Extrapelvic Recurrences
ESGO eAcademy, Neville F. Hacker, 117582
Systematic BRCA1/2 Genetic Testing in Unselected Epithelial Ovarian Cancer- Results from the Gteoc Study
ESGO eAcademy, Robin Crawford, 117576
Reconstructive Procedures After Pelvic Exenteration
ESGO eAcademy, Luis M. Chiva, 117581
LAPAROSCOPY TO PREDICT THE RESULT OF PRIMARY CYTOREDUCTIVE SURGERY IN ADVANCED OVARIAN CANCER (LAPOVCA): A MULTICENTRE RANDOMISED CONTROLLED TRIAL.
ESGO eAcademy, Marrije Buist, 117575
Update on Pelvic Exenteration in 2015
ESGO eAcademy, David Cibula, 117580
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer
ESGO eAcademy, Marco Petrillo, 117574
Engot-OV-6/Trinova-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women with Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer
ESGO eAcademy, Christian Marth, 117573
Palliative and Non-Palliative Surgical Interventions in Relapsed Ovarian Cancer
ESGO eAcademy, Jalid Sehouli, 117579
Targeting HSP-90 in Gynaecological Cancer
ESGO eAcademy, Nicole Concin, 117567
New Antiangiogenic and Vascular Disrupting Agents and Their Combinations
ESGO eAcademy, Antonio Casado, 117566
RAS RAF MEK ERK Pathway
ESGO eAcademy, Cristiana Sessa, 117565
Potential Interest and Place of Uterine Transplantation in Gynaecologic Oncology
ESGO eAcademy, Yves Aubard, 117563
Oncologic Risk in Immuno-Suppressed Patients for Transplantation
ESGO eAcademy, Josep M. Grinyó, 117562
First Results of Uterus Transplantation in Human
ESGO eAcademy, Pernilla Dahm-Kähler, 117561
How To Manage BRCA Mutated Patients?
ESGO eAcademy, Eric Pujade-Lauraine, 117551
Surgical and Systemic Treatment of Recurrences
ESGO eAcademy, Andreas Du Bois, 117550
Putting It All Together: the Impact of a Comprehensive, Standardised Enhanced Recovery Programme
ESGO eAcademy, Sean C. Dowdy, 117554
Systemic Therapy: from Chemotherapy to Targeted Therapy in Front Line and at Recurrence
ESGO eAcademy, Nicoletta Colombo, 117549
The Role of Nutrition in Perioperative Recovery
ESGO eAcademy, Federico Bozzetti, 117553
Surgical Treatment of Primary and Recurrent Ovarian Cancer
ESGO eAcademy, Émile Darai, 117548
How Anesthesia Can Improve Postoperative Recovery
ESGO eAcademy, Stephanie Suria, 117552
Horizon Scanning-Emerging Strategies for Recurrent Disease
ESGO eAcademy, Cristiana Sessa, 117546
Advanced Stage with Emphasis on Management of Patients with Positive Paraaortic Nodes
ESGO eAcademy, Christine Haie-Meder, 117537
Current Options for Relapsed Cervical Cancer
ESGO eAcademy, Jonathan Ledermann, 117545
Surgical Management of Early Disease
ESGO eAcademy, Nicoletta Colombo, 117544
Rationale and Evidence for Tailored Approach to Early Stage Disease
ESGO eAcademy, David Cibula, 117536
Managing Early Relapse- Experimental Therapeutics
ESGO eAcademy, Cristiana Sessa, 117543
Current Choices for First Line Therapy
ESGO eAcademy, Jonathan Ledermann, 117542
Surgery or Neoadjuvant Chemotherapy
ESGO eAcademy, Nicoletta Colombo, 117541
Update on Fertility Sparing Treatment
ESGO eAcademy, Nadeem Abu Rustum, 117535
Importance of Multidisciplinary Management of Gynaecological Cancers
ESGO eAcademy, Jonathan Ledermann, 117540
Clinical Trial for Rare Tumours: List of Ongoing and Future Clinical Trials in EU and Unanswered Questions
ESGO eAcademy, Isabelle Ray-Coquard, 117530
Peritoneal Mesothelioma: Who Benefits from Radical Surgery?
ESGO eAcademy, Marcello Guaglio, 117533
Current Management of Appendiceal Neoplasia and Pseudomyxomes Peritonei
ESGO eAcademy, Sarah O'Dwyer, 117532
Organisation of Health Care Providers for the Treatment of Rare Peritoneal Malignancies: the French Way (Renape)
ESGO eAcademy, Olivier Glehen, 117531
Stage IV Ovarian Cancer: Prognosis of Patients with Exclusively Abdominal Wall Metastasis
ESGO eAcademy, Florian Heitz, 117712
The Impact of Lymph Node Dissection and Adjuvant Chemotherapy on Survival in Early-Stage Ovarian Cancer. Data of 3658 Patients
ESGO eAcademy, Marjolein Kleppe, 117525
Outcome of 129 Children After Antenatal Exposure to Cancer Treatment: Results of a Case-Control Study from the International Network on Cancer, Infertility and Pregnancy Registry
ESGO eAcademy, Frederic Amant, 117524
Prospective Evaluation of Lymphocele Incidence in Patients After Pelvic and Paraaortic Lymphadenectomy and Analysis of Risk Factors for Their Development
ESGO eAcademy, Michal Zikan, 117523
CA125 GC1G Criteria: Still Valid in the Era of Targeted and Immunologic Therapies
ESGO eAcademy, Bradley Monk, 116825
Response and Progression Criteria in Trials with Targeted Therapy. Recist and Variation
ESGO eAcademy, Cristiana Sessa, 116824
Response and Progression Criteria in Trials with Cytotoxic Agents: Recist and Variation
ESGO eAcademy, Andrés Poveda, 116822
Available Drugs Targeting the Known Altered Pathways in Ovarian Cancer
ESGO eAcademy, Cristiana Sessa, 116821
Potential Actionable Target Pathways in the Different Types of Ovarian Cancer
ESGO eAcademy, Iain McNeish, 116820
How to Measure the Benefit of Chemotherapy-Free Interval in a Trial with Maintenance Targeted Therapy? The Importance Combined Endpoints
ESGO eAcademy, Bradley Monk, 116819
How to Define Platinum-Resistance or Sensitivity after Several Lines of Treatment?
ESGO eAcademy, Jonathan Ledermann, 116818
Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - CON
ESGO eAcademy, sandro pignata, 116817
Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - PRO
ESGO eAcademy, Mansoor Raza Mirza, 116816
Welcome and Introduction: The Changing Landscape of Clinical Trials in the Era of Targeted and Immunologic Therapies: Different Patient Selection, New Endpoints, New Responsible Criteria
ESGO eAcademy, Nicoletta Colombo, 116815
Possible role of robotics in ERAS
ESGO eAcademy, Eric Lambaudie, 105096
What is the place of sentinel procedures in gynecologic Oncology?
ESGO eAcademy, Rene H.M. Verheijen, 105095
Robotic single-site pelvic lymphadenectomy
ESGO eAcademy, Liliana Mereu, 106938
Endoscopic staging in early stage ovarian cancer
ESGO eAcademy, Eric Lambaudie, 106937
Key Lecture: Critical considerations on Robotic Surgery for the treatment of Endometrial Cancer
ESGO eAcademy, Angelo Maggioni, 105137
What progress is made and expected the coming decade in endoscopic (non-robotic) gynaecological surgery ?
ESGO eAcademy, Farr Nezhat, 105090
Single site robotic hysterectomy
ESGO eAcademy, Fatih Sendag, 105088
Compartment imaging with fluorescence
ESGO eAcademy, K. Rainer Kimmig, 105087
New robots and implementation
ESGO eAcademy, Rene H.M. Verheijen, 105086
Paraaortic lymphadenectomy and surgical approach
ESGO eAcademy, Fabrice Narducci, 105085
Robotic radical trachelectomy
ESGO eAcademy, M. Faruk Kose, 105084
Robotic-assisted radical hysterectomy: oncology outcomes
ESGO eAcademy, Vanna Zanagnolo, 105083
Key lecture: Radical hysterectomy: Overview of the different techniques of parametrial dissection
ESGO eAcademy, K. Rainer Kimmig, 105082
European Reference Network
ESGO eAcademy, Francois Golfier, 99309
Future Perspectives in Gestational Trophoblastic Disease
ESGO eAcademy, Leon Massuger, 99308
PSTT/ETT
ESGO eAcademy, Barry Hancock, 99307
When EMACO Does Not Cure
ESGO eAcademy, Michael Seckl, 99305
Case Report Hi Dose
ESGO eAcademy, Kirsty Balachandran, 99304
Treatment of High Risk Gestational Trophoblastic Disease
ESGO eAcademy, John Tidy, 99303
Case: High Risk Gestational Trophoblastic Disease
ESGO eAcademy, Mireille Vree, 99302
Treatment of Low Risk Gestational Trophoblastic Disease
ESGO eAcademy, John Coulter, 99301
Case: MTX Resistance
ESGO eAcademy, Sam Schoenmakers, 99300
Histologic and Immunohistochemic Features of Trophoblastic Disease
ESGO eAcademy, Sophie Patrier, 99299
Case Report Pathology
ESGO eAcademy, Gwendoline Side-Pfennig, 99298
HCG in Gestational Trophoblastic Disease
ESGO eAcademy, Teun van Herwaarden, 99295
Case: Clinical Consequences of Different hCG Assays
ESGO eAcademy, Yalck Eysbouts, 99294
History of Gestational Trophoblastic Disease
ESGO eAcademy, Rene H.M. Verheijen, 99293
Immunotherapy Represents the Future for Ovarian Cancer
ESGO eAcademy, Bradley Monk, 96876
Immunotherapy Has Never Worked and Will Never Work in Ovarian Cancer
ESGO eAcademy, Eric Pujade-Lauraine, 96875
How To Negotiate Support with Pharma Companies for Sponsored Trials
ESGO eAcademy, Andreas Du Bois, 96873
How To Write a Grant for Academic Trials (Investigator-Initiated)
ESGO eAcademy, sandro pignata, 96872
The Hurdles of Conducting Trials across Different Countries: Focus on EU Regulations and Differences Which May Constitute Barriers to Run an ENGOT Trial
ESGO eAcademy, Jacobus Pfisterer, 96871
The Challenge of Initiating a National Cooperative Trial Group: Tricks and Tips
ESGO eAcademy, Mansoor Raza Mirza, 96870
Outside EU Regulations: Activating a Study in Switzerland
ESGO eAcademy, Cristiana Sessa, 96983
Reversing Mutated p53 to Wild Type
ESGO eAcademy, Sevilay Altintas, 63068
Inhibiting the Gain-of-Function of Mutated p53
ESGO eAcademy, Nicole Concin, 63067
Why Signatures Miss the Goal in Ovarian Cancer
ESGO eAcademy, MICHAEL BIRRER, 63066
Why Signatures Are the Best Way to Identify Subgroups in Ovarian Cancer
ESGO eAcademy, Charlie Gourley, 63065
The Tricky Decision to Allow Cross-Over or Not in a Trial
ESGO eAcademy, Bradley J. Monk, 63064
Funding Options, Legal Aspect and Insurance Hurdles, How To Select Centers for Surgical Trials?
ESGO eAcademy, Jacobus Pfisterer, 63060
What Are the Endpoints and Do We Have the Right Questionnaires for QOL? What Are the Open Questions in Relapse Ovarian Cancer?
ESGO eAcademy, Philipp Harter, 63061
Robotic debulking surgery
ESGO eAcademy, Javier Magrina, 63093
EU reimbursement update and the role of medical expertise in Driving Dr.G change
ESGO eAcademy, Susanne Habetha, 63134
Chance of cost reduction and increase of efficiency in robotic surgery
ESGO eAcademy, Petur Reynisson, 63133
Cost analysis in endometrial cancer patients
ESGO eAcademy, Frederic Goffin, 63132
Cost evaluation (French analysis)
ESGO eAcademy, Eric Lambaudie, 63131
How to implement a registry?
ESGO eAcademy, Eric Lambaudie, 63092
The 'Art of Docking': Key for successful robotic surgery
ESGO eAcademy, Henrik Falconer, 63130
Robotic skills assessment: to score or not score ?
ESGO eAcademy, Henk Schreuder, 63088
Compartment visualization in embryologically defined surgery
ESGO eAcademy, Martin Heubner, 63129
Education in robotics: The U.S. experience
ESGO eAcademy, Gokhan S. Kilic, 63089
Applicability and feasibility of laparoscopic surgery of uterine cancer in patients with BMI under 30. Evaluation of a policy in favor of minimal invasive surgery in a single center
ESGO eAcademy, Denis Querleu, 63126
Perioperative morbidity and outcome analysis of robotically assisted laparoscopic radical hysterectomy
ESGO eAcademy, Fabrice Narducci, 63125
Robotic surgery and technique of radical hysterectomy in cervical and endometrial cancer
ESGO eAcademy, Angelo Maggioni, 63124
Evidence for adequate quality in radical hysterectomy by endoscopy
ESGO eAcademy, Roberto Tozzi, 63123
Present and future development of robotic surgery in gynecology: Visions, expectations and demands
ESGO eAcademy, Ignance Vergote, 63083
RoundTable (Questions&Answers) of State of the Art Conference
ESGO eAcademy, Session Speakers, 62459
Patient´s expectations and perspectives about cancer care in ovarian cancer
ESGO eAcademy, Elena Ioana Braicu, 62458
Follow up of advanced stage invasive ovarian cancers
ESGO eAcademy, Gordon J.S. Rustin, 62457
Follow up of early stage invasive ovarian cancer, fertility sparing treatment
ESGO eAcademy, Rene H.M. Verheijen, 62456
Non epithelial ovarian tumours
ESGO eAcademy, Nicoletta Colombo, 62455
Borderline ovarian tumor follow up
ESGO eAcademy, Philippe Morice, 62454
Familial risk and its management
ESGO eAcademy, Usha Menon, 62453
Imaging strategies for follow up
ESGO eAcademy, Nandita de SOUZA, 62451
Imaging strategies for follow up
ESGO eAcademy, Manuela LUDOVISI, 62452
The Role of the Pathologist in Planning Follow up
ESGO eAcademy, Silvestro CARINELLI, 62450
The Role of Biomarkers in the Follow up in Ovarian Cancer
ESGO eAcademy, Massimo GION, 62449
Take home message of State of the Art Conference
ESGO eAcademy, K. Rainer Kimmig, 62446
RoundTable (Questions&Answers) of State of the Art Conference
ESGO eAcademy, Panel, 62444
Follow up of special histotypes including sarcomas
ESGO eAcademy, Nicholas Reed, 62443
Follow up after the treatment of endometrial cancer
ESGO eAcademy, ENRICO SARTORI, 62442
Endometrial cancer: Familial risk and its management
ESGO eAcademy, Usha Menon, 62441
Imaging strategies in the follow-up of endometrial cancer
ESGO eAcademy, Nandita de SOUZA, 62439
Imaging strategies for follow up
ESGO eAcademy, Manuela LUDOVISI, 62440
The Role of the Pathologist in Planning Follow up
ESGO eAcademy, Sigurd Lax, 62438
Take home message of State of the Art Conference
ESGO eAcademy, Tiziano Maggino, 62434
Take home message of State of the Art Conference
ESGO eAcademy, David Cibula, 62435
RoundTable (Questions&Answers)of State of the Art Conference
ESGO eAcademy, Session Speakers, 62433
Follow up after integrated therapy
ESGO eAcademy, Nicholas Reed, 62432
Follow up after surgical treatment
ESGO eAcademy, Tiziano Maggino, 62431
Imaging strategies for follow up
ESGO eAcademy, Nandita de SOUZA, 62429
Imaging Strategies for follow up
ESGO eAcademy, Manuela LUDOVISI, 62920
The Role of the Pathologist in Planning Follow up in Endometrial Cancer
ESGO eAcademy, Sigurd Lax, 62428
The Obstetrics Management after fertility sparing Treatment
ESGO eAcademy, Tullia TODROS, 62427
Follow up after Fertility Sparing Treatment
ESGO eAcademy, Fabio Landoni, 62426
Follow up after the treatment of cervical pre-cancer and microinvasive cancer
ESGO eAcademy, Vesna Kesic, 62425
The cost of follow up: looking for efficacy and effectiveness
ESGO eAcademy, Giovannino CICCONE, 62419
The psychological impact of the follow up procedures
ESGO eAcademy, Eva Greimel, 62418
Risk of secondary cancer after treatment of gynaecological cancer
ESGO eAcademy, David Cibula, 62417
The role of the imaging (CT-RMI-PET/CT) in the follow up
ESGO eAcademy, Nandita de SOUZA, 62416
The role of ultrasound procedures in the follow up
ESGO eAcademy, Manuela LUDOVISI, 62415

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings